• Sonja Babovic and Kishor M Wasan.
• University of British Columbia, Faculty of Science and Pharmaceutical Sciences, Vancouver, British Columbia, Canada V6T 1Z3. babovics@interchange.ubc.ca
• J Pharm Sci. 2011 Mar 1; 100 (3): 816-21.

AbstractThis is a commentary on how the trade-related aspects of intellectual property rights (TRIPS) agreement has impacted India as a supplier of generic antiretrovirals (ARVs). We provide a systematic review of the issues related to the TRIPS agreement that affects India. This includes discussion around (a) the legal landscape underpinning India as a supplier of generic ARVs; (b) supply of second-line ARVs; and (c) the future of generic drug production in India. The proclamation into force of TRIPS-compliant intellectual property law in India is likely to affect its position as a supplier of affordable ARVs, especially drugs brought to market after 2005. Currently, mechanisms exist for the generic production of almost all ARVs in India, including second-line drugs; however, the manufacture of these drugs by generic pharmaceutical companies may require additional market incentives. Compulsory licensing may emerge as an additional mechanism by which India can provide affordable versions of patented drugs to Least Developed Countries (LDCs).Copyright © 2010 Wiley-Liss, Inc.

14 keywords...

hide…